Final Program - American Society of Gene & Cell Therapy

Program Schedule, Saturday, May 18, 2013
Michael A. Lalamme, MD, PhD
Cardiac Repair with Human Pluripotent Stem Cells
Human pluripotent stem cells have a number of potential advantages for use in myocardial infarct repair, including tremendous
capacity for expansion in the undifferentiated state and unambiguous cardiac potential. Our group irst reported what are now
widely applied methods to eficiently guide the differentiation of human embryonic stem cells (hESCs) and induced pluripotent
stem cells (hiPSCs) into cardiomyocytes, as well as their further differentiation to speciic cardiac subtypes (e.g. pacemaker or
ventricular myocytes). In early proof-of-concept studies using a rat infarct model, we showed that the transplantation of hESCderived
cardiomyocytes results in partial remuscularization of the infarct scar and improved contractile function. More recently,
we have used a guinea pig infarct model to show that hESC-derived cardiomyocyte grafts can integrate electrically and contract
synchronously with host muscle; and that these grafts exert an intriguing arrhythmia-suppressive effect. Our ongoing efforts are
focused on promoting the structural and functional maturation of hESC-derived cardiomyocytes, as well as their electromechanical
integration in vivo.
Ann M. Leen, PhD
T cell Therapy for Viruses and Cancer
Severe and fatal viral infections remain common after hematopoietic stem cell transplantation. Adoptive transfer of in vitro
expanded cytotoxic T lymphocytes speciic for EBV, CMV and Adv antigens can treat infections that are impervious to conventional
therapies. However, the time taken to prepare patient-speciic products, the limited breadth of viral speciicities that can be
accommodated in a single line, and the lack of virus-speciic T-cells in cord blood and seronegative donors restricts application. In
this presentation I will summarize our preclinical efforts to address these limitations and will present our clinical trial results using
these products.
Oral Abstract Session 410
10:15 am - 12:15 pm
ROOM: 150 DEFG
Late Breaking Abstracts
CO-CHAIRS: TO BE DETERMINED
(Abstracts 725 through 732; see page 124)
Saturday, May 18, 2013
Oral Abstract Session 411
10:15 am - 12:15 pm
ROOM: 150 ABC
Adenovirus and Other DNA Virus Vectors
CO-CHAIRS: Prem Seth, PhD and Miguel Sena-Esteves, PhD
(Abstracts 477 through 484; see pages 124-125)
70
Final Program SALT LAKE CITY, UTAH May 15–18, 2013